主页 > 医药生命 >

【drug-news】惠氏药厂要求法院阻止Protonix 仿制药

Wyeth Asks Court to Prevent Generic Drug Makers From Launching Versions of Protonix

NEW YORK (AP) -- Pharmaceutical company Wyeth is seeking a preliminary injunction to prevent two generic drug makers from selling versions of acid reflux treatment Protonix, according to a filing with the Securities and Exchange Commission.The preliminary injunction would prevent Teva Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Ltd. from marketing generic pantoprazole sodium tablets until the court reaches a final decision about related patent litigation.

Wyeth's motion was filed with the U.S. District Court for the District of New Jersey on Friday.

The litigation against Teva was first filed by Wyeth and Altana Pharma AG, which has been acquired by Nycomed Holding AS, in May 2004. As a result of the filing, final Food and Drug Administration approval of Teva's abbreviated new drug application was automatically stayed until Aug. 2.

Altana and Wyeth filed suit against Sun in April 2005. Subsequently, final FDA approval of Sun's application was held until Sept. 8.

Wyeth is seeking the preliminary injunction to prevent the companies from launching their generics after the stays expire. The cases have been consolidated into a single proceeding, but no trial date has been set.

Wyeth said it believes it has "a strong basis for seeking a preliminary injunction to prevent an early generic launch" but cannot guarantee a favorable result. The patent, which is owned by Altana, expires in July 2010.

In the first quarter, sales of Protonix totaled $474 million.

Wyeth shares gained 66 cents to $56.55 in midday trading. 本人认领本文,48小时后若未提交译文,请其他战友自由认领。 [标签:content1][标签:content2]

阅读本文的人还阅读:

【drug-news】FDA批准武田制

【drug-news】日本大冢制药

作者:admin@医学,生命科学    2011-03-13 05:12
医学,生命科学网